Skip to main content
. 2020 Oct 20;10:17769. doi: 10.1038/s41598-020-72475-9

Figure 2.

Figure 2

Flow chart illustrating the patient selection criteria. EC endometrial cancer, CE-CT contrast-enhanced computed tomography, NACT neoadjuvant chemotherapy, POLE polymerase epsilon, MMR-D DNA mismatch repair-deficient, CN copy number.